Saluda Medical's Surgical Paddle Lead Approved by FDA, Shares Soar 18%

MT Newswires Live
06/30

Saluda Medical (ASX:SLD) said the US Food and Drug Administration (FDA) approved its CAP24 surgical paddle lead, an alternative to percutaneous leads, allowing them to be marketed and sold in the US for spinal cord stimulation, according to a Thursday Australian bourse filing.

The firm plans a phased US launch beginning in the second half of the year, with a broader commercial rollout starting later in the year.

Its shares soared 18% in recent trading on Tuesday.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10